Xellia Pharmaceuticals has broken ground on the new $25 million expansion at its Copenhagen site.
This site houses Xellia’s headquarters and is the Company’s largest product manufacturing plant.
The ceremony celebrated the start of construction of a new state-of-the-art multi-story building that will house the latest sterile manufacturing equipment and containment solutions in a purpose built environment.
Xellia’s Copenhagen site is responsible for manufacturing, stability testing and packaging of both sterile Active Pharmaceutical Ingredients and the Finished Dosage Forms for anti-infectives – such as vancomycin and colistmethate sodium.
This upgrade in facilities will ensure that Xellia is able to continue to provide a reliable supply of injectable anti-infective critical care medicines and remain at the forefront of manufacturing excellence.